|Bid||0.00 x 90000|
|Ask||0.00 x 90000|
|Day's range||106.00 - 106.00|
|52-week range||65.95 - 151.00|
|Beta (5Y monthly)||1.04|
|PE ratio (TTM)||32.29|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Incyte (INCY) and partner MorphoSys' application for tafasitamab gets validation by EMA.
Image source: The Motley Fool. MorphoSys AG (NASDAQ: MOR)Q1 2020 Earnings CallMay 9, 2020, 8:30 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorLadies and gentlemen, welcome to MorphoSys First Quarter 2020 Results Conference Call.
MorphoSys (ETR:MOR) has had a great run on the share market with its stock up by a significant 24% over the last...